VIDEO: CheckMate 9ER data show ‘clinically meaningful benefit’ in long-term survival
Click Here to Manage Email Alerts
SAN FRANCISCO — Healio spoke with Toni K. Choueiri, MD, about follow-up data from the CheckMate 9ER presented at ASCO Genitourinary Cancers Symposium.
The phase 3 CheckMate 9ER trial compared nivolumab (Opdivo, Bristol Myers Squibb) plus cabozantinib (Cabometyx, Exelixis) with sunitinib (Sutent, Pfizer) for the treatment of advanced renal cell carcinoma in the first-line setting. According to Choueiri, senior author on the abstract, results from this trial led to the FDA approval of the nivolumab/cabozantinib combination as a front-line therapy.
The researchers investigated the long-term outcomes in a 3-year follow-up.
“We saw that the doublet of cabozantinib/nivolumab maintained clinically meaningful benefit in long-term survival versus sunitinib,” Choueiri, Jerome and Nancy Kohlberg professor of medicine at Harvard Medical School and attending physician in solid tumor oncology, director of the Genitourinary Oncology Disease Center, and director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, said.
Reference:
- Burotto M, et al. Abstract 603. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2023; San Francisco.
Collapse
Healio Interviews
Click Here to Manage Email Alerts